` MIST (Milestone Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

MIST
vs
S&P 500

Over the past 12 months, MIST has outperformed S&P 500, delivering a return of +16% compared to the S&P 500's +14% growth.

Stocks Performance
MIST vs S&P 500

Loading
MIST
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MIST vs S&P 500

Loading
MIST
S&P 500
Difference
www.alphaspread.com

Performance By Year
MIST vs S&P 500

Loading
MIST
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Milestone Pharmaceuticals Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Milestone Pharmaceuticals Inc
Glance View

Market Cap
183.1m USD
Industry
Pharmaceuticals

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 29 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate is etripamil. The etripamil is a novel, potent and short-acting calcium channel blocker that has been designed rapid-onset nasal spray, which is self-administered by patients. The firm is developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF) and rapid ventricular rate, and other cardiovascular indications.

MIST Intrinsic Value
Not Available
Back to Top